Salvage surgery for locally recurrent prostate cancer after radiation therapy

Urologic Oncology

Volumn 4, Issue 2, 1998, Pages 31-38

  Tefilli, Marcos V ^a,b   Gheiler, Edward L ^a,b   Wood Jr , David P ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Local recurrence; Prostate cancer; Radiotherapy; Salvage surgery

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SALVAGE THERAPY; TREATMENT PLANNING;

EID: 0032481679     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(98)00029-5     Document Type: Review

References (39)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin. 47:1997;5-27.
2. Partin A.W., Pound C.R., Clemens J.Q., Epstein J.I., Walsh P.C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin N Am. 20:1993;713-725.
3. Lee W.R., Hanbon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer. The relationship between nadir level and disease-free survival J Urol. 156:1996;450-453.
4. Schellhammer P.F., Kuban P.A., El-Mahdi A.M. Treatment of clinical local failure after radiation therapy for prostate cancer. J Urol. 150:1993;1851-1855.
5. Moul J.W., Paulson D.F. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 68:1991;1265-1269.
6. Lerner S.E., Blute M.L., Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol. 154:1995;1103-1109.
7. Spaulding J.T., Whitmore W.F. Jr. Extended total excision of prostatic adenocarcinoma. J Urol. 120:1978;188-192.
8. Rogers E., Ohori M., Kassabian V.S., Wheeler T.M., Scardino P.T. Salvage radical prostatectomy. Outcome measured by serum specific antigen levels J Urol. 153:1995;104-110.
9. Gheiler E.L., Tefilli M.V., Tiguert R.et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 51:1998;789-795.
10. Oefelein M.G., Smith N., Carter M., Dalton D., Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 154:1995;2128-2131.
11. Zeitman A.L., Coen J.J., Shipley W.U., Willet C.G., Efird J.T. Radical radiation therapy in the management of prostatic adenocarcinoma. The initial prostate specific antigen value as predictor of treatment outcome J Urol. 151:1994;640-643.
12. Lee W.R., Hanks G.E., Schultheiss T.E., Corn B.W., Hunt M.A. Localized prostate cancer treated by external beam radiotherapy alone. Serum PSA driven outcome analysis J Clin Oncol. 13:1995;464-468.
13. Liebel S.A., Zelefsky M.J., Kutcher G.J., Burman C.M., Kelson S., Fucks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate. Interim report of a phase 1 dose-escalation study J Urol. 152:1994;1792-1795.
14. Pisansky T.M., Cha S.S., Earle J.D.et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2161.
15. Zagars G.K., Polack A. Radiation therapy for T1 and T2 prostate cancer. Prostate-specific antigen and disease outcome Urology. 45:1995;476-480.
16. Critz F.A., Levinson K., Williams W.H., Holladay D., Holladay C., Griffin V. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology. 49:1997;668-672.
17. Scardino P.T., Frankel J.E.F., Wheeler T.M. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol. 135:1986;510-516.
18. Scardino P.T., Wheeler T.M. Local control of prostate cancer with radiotherapy. Frequency and prognostic significance of positive results of postirradiation prostate biopsy NCI Monogr. 1:1988;95-100.
19. Tefilli M.V., Gheiler E.L., Tiguert R.et al. Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer. Urology. 52:1998;224-229.
20. Pontes J.E., Montie J., Klein E., Huban R. Salvage surgery for radiation failure in prostate cancer. Cancer. 71:1993;976-981.
21. Schellhammer P.F., El-Mahdi A.M., Kuban D.A., Wright G.L. Prostate-specific antigen after radiation therapy. Urol Clin N Am. 21:1997;407-414.
22. Grob B.M., Schellhammer P.F., Brassil D., Wright G.L. Jr. Changes in immunohistochemical staining of PSA, PAP and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urology. 44:1994;525-529.
23. Garzotto M., Wajsman Z. Androgen deprivation with salvage surgery for radiorrecurrent prostate cancer. Results at 5-year follow up J Urol. 159:1998;950-955.
24. Pontes J.E. Surgery of genitourinary pelvic tumors - An anatomic atlas. 1993;Wiley, New York.
25. Pontes J.E. Role of surgery in managing local recurrence following external-beam radiation therapy. Urol Clin N Am. 21:1994;701-706.
26. Gheiler E.L., Wood D.P. Jr., Montie J.E., Pontes J.E. Orthotopic urinary diversion is a viable option in patients undergoing salvage cystoprostatectomy for recurrent prostate cancer after definitive radiation therapy. Urology. 50:1997;580-584.
27. Link P., Freiha F.S. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology. 27:1991;189-192.
28. Thompson I.M., Rounder J.B., Spence C.R., Rodrigues F.R. Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer. 61:1988;1464.
29. Neehut G.J., Wheeler T., Cantini M., Scardino P.T. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol. 140:1988;544-548.
30. Ahlering T.E., Lieskovsky G., Skinner D.G. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol. 147:1992;900-904.
31. Stein A., Smith R.B., deKernion J.B. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of the prostate. Urology. 40:1992;197-200.
32. Forman J.D., Meetze K., Pontes J.E.et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol. 158:1997;1436-1440.
33. Litwin M.S., Fine J.T., Dorey F.D., Figlin R.A., Belldegrun A.S. Health related quality of life outcomes in patients treated for metastatic kidney cancer. A pilot study J Urol. 157:1997;1608-1612.
34. Cella D.F., Tulsky D.S., Gray G.et al. The functional assessment of cancer therapy subscale. Development and validation of general measure J Clin Oncol. 3:1993;570-579.
35. 125 seeds implants for prostatic carcinoma. Urology. 41:1993;122-125.
36. Ritter M.A., Messing E.M., Shanahan T.G., Potts S., Chappell R.J., Kinsella T.J. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 10:1992;1208-1211.
37. 125I implantation. Br J Urol. 74:1994;44-47.
38. Loening S., Hawtrey C., Bonney W., Narayana A., Culp D.A. Cryotherapy of prostate. Prostate. 1:1980;279-286.
39. Grampsas S.A., Miller G.J., Crawford E.D. Salvage radical prostatectomy after failed transperineal cryotherapy. Histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images Urology. 45:1995;936-941.